Correlation between oncogenes (HER2/neu and BCL2), tumor suppressor gene (p53), tumor proliferation rate (proliferating cell nuclear antigen), and specimen pathological variables in prostatic cancer patients, operated in Hospital Sírio Libanês, São Paulo. Here, ERBB2 is linked to prostate carcinoma.